Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2020: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2019: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Outline of Final Research Achievements |
We developed a methodology that enables efficient ribosomal incorporation of nonproteinogenic amino acids, such as D-amino, β-amino, γ-amino, and N-methyl-amino acids, into nascent peptides. By means of this system, we constructed macrocyclic random peptide libraries bearing those nonproteinogenic amino acids and applied them to mRNA display-based in vitro selection against various disease-related target proteins. The obtained macrocyclic peptides exhibited extremely high binding affinity, inhibitory activity, and serum stability.
|